brenetafusp
Sponsor Immunocore Holdings PLC · listed as IMCR
READOUT
Phase 3
Confidence: medium
Source: clinicaltrials
brenetafusp is a clinical-stage drug asset sponsored by Immunocore Holdings PLC, listed as IMCR. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Oct 16, 2027 (day precision, medium confidence), tied to trial NCT06112314. The asset is in Phase 3 and currently recruiting, studied in Advanced Melanoma.
Next catalyst
Event typeREADOUT
Expected date2027-10-16
As disclosedOct 16, 2027
Date precisionday
Confidencemedium
Trial & sponsor
Trial (NCT)NCT06112314
PhasePHASE3
StatusRECRUITING
Lead sponsorImmunocore Ltd
Listed asIMCR
Condition(s)Advanced Melanoma
!
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This is one row of the free CSA sample. The full snapshot carries 2,221 forward catalysts, 955 of them linked to 124 listed sponsors.
Get the full dataset — $499 → More IMCR catalysts